Articles tagged with Immune Response
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
Rumbaugh's lab aims to understand the effects of dispersing bacteria from a biofilm on their susceptibility to antibiotics and on the host. They will use enzymes as tools to break up biofilms, allowing researchers to better comprehend the relationship between bacterial dispersal and infection outcomes.
Researchers have discovered a previously unknown mechanism behind immune tolerance, where B cells teach T cells to ignore the body's own proteins. This failure can lead to autoimmune diseases such as Multiple Sclerosis-like Neuromyelitis optica.
A recent study published in the Journal of Clinical Medicine identifies potential biomarkers for ME/CFS diagnosis and treatment. Researchers found that patients can be divided into subgroups based on immune system function, revealing differences in intestinal barrier function and immune competence.
Scientists discovered a novel mechanism for removing mtDNA from mitochondria, which can initiate an immune response promoting inflammation. The discovery reveals new targets for therapeutics to disrupt the inflammatory pathway and mitigate inflammation during aging and diseases.
Researchers found a four-fold increase in immune response when people alternate arms during two-dose vaccinations. The study showed improved immunity to the original and omicron variants after three weeks and persisted beyond 13 months.
Researchers have found that alterations in the blood immune system increase cancer risk, and identified over 1,000 genes influencing this regulation. The study also discovered protective roles of certain immune cells against common cancers.
Researchers have discovered that immune cells can form memories of pathogens at multiple phases during an infection, with the ability to switch between memory and effector cell fates. This flexibility enables individuals to better adapt to uncertain situations and respond effectively to different threats.
Researchers found XRCC1 to have both positive and negative correlations with prognosis across different tumors. The study also revealed associations between XRCC1 expression and DNA methylation patterns, TMB, MSI, immune cell infiltration levels, and immune checkpoint gene expression.
A new study finds that infants born full-term to mothers infected with COVID-19 during pregnancy are three times more likely to develop respiratory distress compared to uninfected infants. Vaccination prior to infection was found to be protective, reducing the risk by half.
Researchers have unraveled the activation mechanism of GBP1, a protein that encapsulates bacterial pathogens with an antimicrobial coat. The study reveals how GBP1 forms a protein coat around invaders, destroying their membrane and preventing multiplication.
Researchers analyzed LTBR expression levels in various cancers, finding it associated with low patient survival and immune cell infiltration. The study identified LTBR as a potential target for cancer immunotherapy and marker of poor prognosis.
Researchers found that the complement system remains activated in Long Covid patients, causing cell damage and tissue destruction. This abnormal activity can lead to thromboinflammation and other symptoms of the condition.
A new vaccine design has been developed by a UC Riverside-led research team, which uses preexisting immunity to the influenza virus to help kickstart the production of antibodies against SARS-CoV-2. The vaccine aims to speed up the immune response and provide better protection for people who still lack immunity to the coronavirus.
Researchers at UC San Diego School of Medicine found that the immune system's response to Staphylococcus aureus bacteria can be tricked into producing non-protective antibodies, making vaccines ineffective. The study suggests targeting subdominant antigens for future vaccine development.
Research suggests that structural changes in upper motor neurons send a signal to immune cells, leading to toxic effects on neurons and reduced synaptic connections. Blocking inflammation with a semi-synthetic drug can restore synaptic connections and improve ALS symptoms.
Researchers at Karolinska Institutet have developed a nasal spray with IgA antibodies that can protect mice from SARS-CoV-2 infection. The treatment significantly diminished virus load in infected mice and showed stronger binding to the spike protein compared to original IgG antibodies.
Researchers from UTHealth Houston discovered that Epstein-Barr virus (EBV)-specific T-cells are present in high numbers in the cerebrospinal fluid of people with multiple sclerosis at its earliest stages. The study suggests that these cells may be contributing to the disease's pathogenesis.
A new study by University of California Riverside researchers found that high-fat diets affect not only obesity and colon cancer but also the immune system, brain function, and potentially COVID-19 risk. The study, which analyzed genetic changes in mice fed different types of fat, showed that polyunsaturated fatty acids in soybean oil ...
New Harvard study finds that perceived time influences actual physical healing time, challenging conventional beliefs about psychological influence on health. The study used a standardized procedure to mildly wound volunteer subjects and found that wounds healed faster when participants believed more time had passed.
Researchers have developed nanodrones that target and eliminate cancer cells by recruiting natural killer cells to tumor sites. The study offers a potential solution for intractable types of cancers, with promising results in suppressing tumor growth without causing side effects.
Gladstone scientists have created an intricate map of how the immune system functions, examining the detailed molecular structures governing human T cells. This study will accelerate the development of new and better therapies for cancer and autoimmune diseases.
A new study found that HSP10 treatment improved exploratory preferences, object contacts, and swimming time in aged mice, while also increasing proliferating cells and differentiated neuroblasts. The protein also mitigated age-related gene reductions and increased sirtuin 3 levels.
Two Melbourne-made COVID-19 vaccines demonstrated strong boosting capabilities against SARS-CoV-2 variants in a Phase 1 clinical trial. The vaccines focus the immune response on the receptor binding domain, potentially providing a more efficient approach to boost immunity.
Researchers have identified a sequence within therapeutic mRNAs that causes unintended immune responses and found a way to correct these errors. By designing 'slip-resistant' mRNAs, the team aims to produce future mRNA vaccines with improved safety and efficacy.
Scientists at the University of Pennsylvania's School of Veterinary Medicine have identified a novel type of lymphoid microenvironment in fish that generates antibody responses. This discovery has significant implications for understanding immune system evolution and developing effective vaccines for the aquaculture industry.
Researchers confirm that pancreatic cancer triggers a response in the immune system, but T cells struggle to infiltrate tumors. This finding could guide future treatment development for pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer.
Scientists at University of Toronto and Sinai Health created transplants with genetic modification, persisting long-term in mice without immune suppression. This breakthrough may transform cell therapies for incurable diseases, making transplantation safer and more widely available.
A new study found that a half-dose of the Pfizer COVID-19 booster vaccine elicited a non-inferior immune response to a full dose in Mongolian adults, with fewer side effects. The study suggests that fractional dosing may improve booster acceptability and reduce costs.
Researchers found that tumor-resident T-cell receptor sequences showed high complementarity with the cancer testis antigen DDX53, suggesting an immune response that selects for DDX53-negative cells. This association was correlated with worse disease-free survival rates, highlighting a potential early esophageal cancer antigen.
Treatment with obinutuzumab has been shown to preserve kidney function and prevent flares in patients with lupus nephritis. The addition of obinutuzumab to standard treatment reduced the risk of composite outcomes, such as death or treatment failure, by 60%.
Researchers at Trinity College Dublin discovered that autism-induced maternal immune response alters brain development and prevents infantile amnesia. Memories formed during infancy can be permanently reinstated through light-activated neural pathways in adults.
A recent study found that transient inflammatory pain causes persistent mitochondrial and metabolic disturbances in sensory neurons, leading to failure in pain resolution. Targeting the cellular redox balance prevents and treats chronic inflammatory pain in rodents.
Salk researchers identify Foxp3 as the protein that determines regulatory T cell genome structure and fate, enabling manipulation to treat autoimmunity or fight cancer. The study reveals Foxp3's essential role in creating unique chromatin architecture of regulatory T cells.
A team of Spanish scientists discovered profound changes in dendritic cells during the immune response, which could lead to novel vaccines against bacterial and viral infections. The study found increased lipid peroxidation and MHC-I upregulation in post-synaptic dendritic cells, triggering efficient priming of CD8+ T cells.
Researchers have discovered that mitochondrial respiration failure leads to genetic and metabolic reprogramming of T cells, causing their functional exhaustion. However, pharmacological or genetic optimization of cellular metabolism can increase T cell longevity and functionality.
Scientists at the University of Würzburg have observed a new behavior of regulatory T cells, which remain in certain lymph nodes for months and function as local memory banks of the immune system. This discovery could lead to therapeutic applications in allergies and autoimmune diseases.
A new tool has been developed to rapidly grow cancer-killing white blood cells, called T cells, which could advance the availability of immunotherapy. The bioreactor is 30% faster than current technologies and can be self-contained in a sterile cabinet.
Researchers at Institute for Systems Biology have made a breakthrough discovery about T cells, finding that the genetically encoded T-cell receptor sequence determines a T cell's function. This fundamental discovery has huge potential for developing custom immune responses to specific antigens.
Researchers used dynamic total-body PET scans to visualize immune T cell distribution in recovering patients. The study found increased concentrations of CD8+ T cells in the bone marrow of recovering COVID patients compared to healthy controls.
In a phase I trial, an oncolytic virus treatment designed by Brigham researchers extended survival among patients with recurrent glioblastoma, especially those with pre-existing viral antibodies. The therapy reshaped the tumor's surrounding environment to stimulate an anti-tumor immune response.
Researchers developed a nanocapsule that reduces lactate levels and releases hydrogen peroxide, recruiting and activating immune cells to attack tumors. The approach increased immune cell activity by 2-5-fold, improving cancer immunotherapy success rates.
Researchers identified a 'guard mechanism' controlling protein GPB1 to attack microbes and cancer cells. The study found that disrupting this mechanism can kill pathogens like Toxoplasma and potentially treat cancer.
A new study reveals that immunity to SARS-CoV-2 variants depends on previous exposure and vaccination history. The research found significant differences in immune responses to various variants, highlighting the need for personalized vaccine approaches.
A new nasal vaccine is being developed to provide long-term protection against Streptococcus A, a deadly bacteria causing 700 million human infections annually. The vaccine approach uses a liposome-based delivery system and has shown robust local protective immunity.
Scientists have developed a trivalent vaccine candidate that provides broad and long-lasting protection against COVID-19 infection by delivering the vaccine via the nose. The vaccine triggers a strong neutralizing antibody response and protects mucosal areas, preventing disease symptoms.
Researchers from Karolinska Institutet challenge the hygiene hypothesis by showing that mice with high infectious exposures have a similar ability to develop allergic immune responses as laboratory mice. Despite this, they developed strong signs of pathological inflammation and allergic responses when exposed to allergens.
A Boston University-led study identified genetic signatures of TB-susceptible and TB-resistant macrophages, leading to a new approach to tweak the immune system to fight the disease. The research could lead to therapies targeting host immunity to tuberculosis.
Research finds that immune cells in older adults are similar to those in newborns and children, but less effective at recognizing infected cells. The study, published in Nature Immunology, suggests that tailored vaccines and therapies could be developed for different age groups based on the unique characteristics of killer T cells.
Researchers discovered that fine-tuning mitochondrial energy production reduces melanoma tumor growth and enhances immune response in mice. The study reveals that manipulating mitochondrial electron transport increases expression of immune genes and makes tumor cells more visible to killer T cells.
A study published in eBioMedicine identified 9 sets of biomarkers, both metagenomic and transcriptomic, associated with 30-day mortality in patients with severe community-acquired pneumonia. The biomarkers were validated with an accuracy of 85%, significantly higher than existing clinical prediction models.
Researchers found that beta-blockers can revive exhausted killer T cells, making them better cancer fighters. The study discovered a link between the sympathetic stress response and immune system response to cancer.
A research team at MedUni Vienna has discovered an immunoregulatory protein called Rinl, which could be linked to the development of autoimmune diseases. The identified component controls the development of follicular T helper cells in the immune system.
A large international study led by Danish researchers may have brought us closer to a cure for HIV. The study found that patients who received monoclonal antibodies before pausing their regular treatment experienced a period of virus suppression, and some even saw their immune system partially or completely suppress the virus.
Receiving two doses of BNT162b2 vaccine was associated with lower risk of COVID-19 emergency department and outpatient visits. The risk appeared lower for those with two versus three doses, despite Omicron sublineages becoming dominant.
Researchers at UC Riverside have discovered a new cell type in the thymus that is similar to M cells found in the gut and airways. The newly discovered cells are like gatekeepers, acting as antigen-delivery cells for the immune system in organs such as the intestine and lung.
Researchers discovered that immune cells create local gradients by consuming chemokines, guiding their movement and enhancing directional movement in complex environments. This finding increases understanding of coordinated immune responses and may reveal new strategies for targeting cancer
Researchers aim to identify genetic risk factors and mechanisms underlying virus-induced asthma, using artificial intelligence-based techniques and patient-derived models. The study may lead to personalized prevention campaigns and mechanism-targeted drugs.
Scientists have established the effectiveness of vaccines against leishmaniasis in animal studies, revealing specific molecular-level changes in host cells. The vaccines, created using mutated parasites, prompt distinct immune responses in hosts, offering new insights into their mechanisms and potential applications.
New SARS-CoV-2 variants, such as BQ.11 and XBB.1.5, bind to cells more tightly and evade antibodies more efficiently than earlier variants, allowing reinfections and breakthrough infections. Previous infection or vaccination can generate antibodies that recognize some proteins on newer variants, reducing the risk of serious illness.